Fulton Breakefield Broenniman LLC Sells 9,001 Shares of Eli Lilly and Company $LLY

Key Points

• Fulton Breakefield Broenniman LLC reduced its stake in Eli Lilly by 22.7% in Q4, selling 9,001 shares to hold 30,587 shares valued at about $32.87 million, or roughly 2.1% of its portfolio (its 15th largest position).
• Eli Lilly's FDA‑approved oral GLP‑1 Foundayo is now available with low out‑of‑pocket pricing and expanding distribution (including Amazon Pharmacy, Weight Watchers and GoodRx), which supports near‑term revenue upside, but Novo Nordisk pricing actions and emerging low‑cost generics in India present competitive and pricing risks.

Fulton Breakefield Broenniman LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 22.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,587 shares of the company's stock after selling 9,001 shares during the quarter. Eli Lilly and Company makes up about 2.1% of Fulton Breakefield Broenniman LLC's portfolio, making the stock its 15th biggest position. Fulton Breakefield Broenniman LLC's holdings in Eli Lilly and Company were worth $32,871,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of LLY. Capital Research Global Investors boosted its position in Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company's stock valued at $19,141,787,000 after acquiring an additional 4,332,008 shares in the last quarter. Amundi boosted its position in Eli Lilly and Company by 27.1% during the 3rd quarter. Amundi now owns 4,525,902 shares of the company's stock valued at $3,823,977,000 after acquiring an additional 964,675 shares in the last quarter. Victory Capital Management Inc. boosted its position in Eli Lilly and Company by 47.6% during the 3rd quarter. Victory Capital Management Inc. now owns 2,309,006 shares of the company's stock valued at $1,761,772,000 after acquiring an additional 744,868 shares in the last quarter. Danske Bank A S bought a new stake in Eli Lilly and Company during the 3rd quarter valued at $512,022,000. Finally, Capital International Investors boosted its position in Eli Lilly and Company by 6.1% during the 3rd quarter. Capital International Investors now owns 10,001,509 shares of the company's stock valued at $7,628,447,000 after acquiring an additional 579,381 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA‑approved oral GLP‑1 Foundayo is now available in the U.S.; company pricing guidance shows low commercial out‑of‑pocket entry ($25/month with coverage) and a self‑pay reference (~$149/month), supporting near‑term revenue upside from obesity market penetration. Foundayo now available (PR Newswire)
• Positive Sentiment: Retail and pharmacy distribution is expanding quickly—Amazon Pharmacy will stock Foundayo with same‑day delivery at some kiosks, increasing convenience and potential uptake. Faster distribution can translate into faster revenue recognition. Amazon to stock Foundayo (Reuters)
• Positive Sentiment: Third‑party programs expanding access—Weight Watchers is offering Foundayo through its Med+ offering and GoodRx is broadening GLP‑1 access—both moves could increase prescriptions and reduce friction for patients. Weight Watchers adds Foundayo (Yahoo/Globe)
• Positive Sentiment: Wall Street is expecting strong upcoming results—analyst commentary and previews point to large year‑over‑year EPS growth driven by GLP‑1 sales and broader portfolio strength. Positive analyst notes (e.g., Guggenheim) are supporting sentiment ahead of earnings. Q1 expectations (Barchart)
• Neutral Sentiment: Health‑care sector strength is providing a supportive backdrop for drug stocks today, helping LLY alongside peers. Sector update (Yahoo Finance)
• Neutral Sentiment: Management is investing heavily in R&D and new areas (AI‑driven drug discovery and neuroscience, a reported ~$10B focus) to diversify long‑term growth beyond weight‑loss drugs. This is strategic but longer‑dated. Lilly's $10B AI/neuroscience push (MarketBeat)
• Negative Sentiment: Pricing and margin pressure from competition: Novo Nordisk’s pricing actions and lower‑priced alternatives could cap Lilly’s pricing power for GLP‑1 products. A recent high‑dose Wegovy price cut increases competitive pressure. Novo price pressure (MarketWatch)
• Negative Sentiment: Emerging low‑cost generic copies in India are already denting sales, showing international pricing and IP risks that could weigh on growth in certain markets. India generics pressure (Financial Post)
• Negative Sentiment: Some analysts have issued downgrades or issued cautious notes, creating short‑term headwinds for sentiment despite the product launch. Analyst downgrade note (American Banking News)

Eli Lilly and Company Stock Performance

Shares of LLY opened at $956.49 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The stock has a fifty day moving average price of $985.96 and a 200-day moving average price of $972.98. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The firm has a market cap of $903.71 billion, a PE ratio of 41.68, a P/E/G ratio of 1.11 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same quarter in the prior year, the business posted $5.32 EPS. The business's revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LLY has been the topic of several recent research reports. JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an "overweight" rating in a research report on Thursday, February 5th. Royal Bank Of Canada initiated coverage on Eli Lilly and Company in a research report on Tuesday, February 24th. They set an "outperform" rating and a $1,250.00 target price on the stock. Cantor Fitzgerald increased their target price on Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an "overweight" rating in a research report on Thursday, February 5th. Loop Capital set a $1,200.00 target price on Eli Lilly and Company in a research report on Tuesday, February 10th. Finally, TD Cowen increased their target price on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a "buy" rating in a research report on Thursday, January 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,222.22.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.